HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aronoff, S. L. Articles by Want, L. Search for Related Content PubMed Articles by Aronoff, S. L. Articles by Want, L. Social Bookmarking                What's this?

Glucose Metabolism and Regulation: Beyond Insulin and Glucagon

Address correspondence and requests for reprints to: Barb Schreiner, RN, MN, CDE, BC-ADM, Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121.

Insulin and glucagon are potent regulators of glucose metabolism. For decades, we have viewed diabetes from a bi-hormonal perspective of glucose regulation. This perspective is incomplete and inadequate in explaining some of the difficulties that patients and practitioners face when attempting to tightly control blood glucose concentrations. Intensively managing diabetes with insulin is fraught with frustration and risk. Despite our best efforts, glucose fluctuations are unpredictable, and hypoglycemia and weight gain are common. These challenges may be a result of deficiencies or abnormalities in other glucoregulatory hormones. New understanding of the roles of other pancreatic and incretin hormones has led to a multi-hormonal view of glucose homeostasis.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. L. Martin Beyond Glycemic Control: The Effects of Incretin Hormones in Type 2 Diabetes The Diabetes Educator, May 1, 2008; 34(Supplement_3): 66S - 72S. [Abstract] [Full Text] [PDF]

				B. P. Childs, N. C. Kesty, E. Klein, R. Rubin, and A. Wick Considering Pramlintide Therapy for Postprandial Blood Glucose Control Diabetes Spectr, April 1, 2007; 20(2): 108 - 114. [Abstract] [Full Text] [PDF]

				R. Hood, V. Valentine, S. Mac, and W. H Polonsky Use of Exenatide in Patients With Type 2 Diabetes Diabetes Spectr, July 1, 2006; 19(3): 181 - 186. [Abstract] [Full Text] [PDF]

				D. F. Kruger, C. L. Martin, and C. E. Sadler New insights into glucose regulation. The Diabetes Educator, March 1, 2006; 32(2): 221 - 228. [Abstract] [Full Text] [PDF]

				D. J. Drucker Incretin-based therapies: a clinical need filled by unique metabolic effects. The Diabetes Educator, March 1, 2006; 32(2 Suppl): 65S - 71S. [Full Text] [PDF]

				B. P. Childs Pramlintide Use in Type 1 Diabetes Resulting in Less Hypoglycemia Diabetes Spectr, January 1, 2006; 19(1): 50 - 52. [Full Text] [PDF]

				C. A Schnabel The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 227 - 235. [Abstract] [PDF]